1-11 of 11
Pier Luigi Zinzani
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas

Won Seog Kim, Jake Shortt, Pier Luigi Zinzani, Natalia Mikhailova, Dejan Radeski, Vincent Ribrag, Eva Domingo Domenech, Ahmed Sawas, Karenza Alexis, Michael Emig, Riham Elbadri, Pallavi Hajela, Paulien Ravenstijn, Sheena Pinto, Linta Garcia, Andre Overesch, Kerstin Pietzko, Steven Horwitz
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (1): 65–73.
https://doi.org/10.1158/1078-0432.CCR-24-1913
Published: 06 January 2025
View article titled, A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas
Open the PDF for A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas in another window
Includes: Supplementary data
Journal Articles

PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial

Juan Pablo Alderuccio, Isildinha M. Reis, Mehdi Hamadani, Muthiah Nachiappan, Salman Leslom, Brad S. Kahl, Weiyun Z. Ai, John Radford, Melhem Solh, Kirit M. Ardeshna, Brian T. Hess, Matthew A. Lunning, Pier Luigi Zinzani, Anastasios Stathis, Carmelo Carlo-Stella, Izidore S. Lossos, Paolo F. Caimi, Sunwoo Han, Fei Yang, Russ A. Kuker, Craig H. Moskowitz
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 139–149.
https://doi.org/10.1158/1078-0432.CCR-23-1561
Published: 05 January 2024
View article titled, PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial
Open the PDF for PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study

Grzegorz S. Nowakowski, Dok Hyun Yoon, Anthea Peters, Patrizia Mondello, Erel Joffe, Isabelle Fleury, Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Judith Trotman, Dan Huang, Eva E. Waltl, Mark Winderlich, Nuwan C. Kurukulasuriya, Sumeet Ambarkhane, Georg Hess, Gilles Salles
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18): 4003–4017.
https://doi.org/10.1158/1078-0432.CCR-21-3648
Published: 15 September 2022
View article titled, Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study
Open the PDF for Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study in another window
Includes: Supplementary data
Journal Articles

The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma

Stephen Opat, Alessandra Tedeschi, Kim Linton, Pamela McKay, Bei Hu, Henry Chan, Jie Jin, Magdalena Sobieraj-Teague, Pier Luigi Zinzani, Morton Coleman, Catherine Thieblemont, Peter Browett, Xiaoyan Ke, Mingyuan Sun, Robert Marcus, Craig A. Portell, Kirit Ardeshna, Fontanet Bijou, Patricia Walker, Eliza A. Hawkes, Sally Mapp, Shir-Jing Ho, Dipti Talaulikar, Ke-Shu Zhou, Melannie Co, Xiaotong Li, Wenxiao Zhou, Massimo Cappellini, Chris Tankersley, Jane Huang, Judith Trotman
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (23): 6323–6332.
https://doi.org/10.1158/1078-0432.CCR-21-1704
Published: 01 December 2021
View article titled, The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma
Open the PDF for The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma in another window
Includes: Supplementary data
Journal Articles

RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma

Pier Luigi Zinzani, Thomas Rodgers, Dario Marino, Maurizio Frezzato, Anna Maria Barbui, Claudia Castellino, Erika Meli, Nathan H. Fowler, Gilles Salles, Bruce Feinberg, Nuwan C. Kurukulasuriya, Sascha Tillmanns, Stephan Parche, Debarshi Dey, Günter Fingerle-Rowson, Sumeet Ambarkhane, Mark Winderlich, Grzegorz S. Nowakowski
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (22): 6124–6134.
https://doi.org/10.1158/1078-0432.CCR-21-1471
Published: 15 November 2021
View article titled, RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Open the PDF for RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma

Leo I. Gordon, Jason B. Kaplan, Rakesh Popat, Howard A. Burris, III, Silvia Ferrari, Sumit Madan, Manish R. Patel, Giuseppe Gritti, Dima El-Sharkawi, Ian Chau, John A. Radford, Jaime Pérez de Oteyza, Pier Luigi Zinzani, Swaminathan Iyer, William Townsend, Reem Karmali, Harry Miao, Igor Proscurshim, Shining Wang, Yujun Wu, Kate Stumpo, Yaping Shou, Cecilia Carpio, Francesc Bosch
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (14): 3546–3556.
https://doi.org/10.1158/1078-0432.CCR-19-3239
Published: 15 July 2020
View article titled, Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma
Open the PDF for Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Myron S. Czuczman, Marek Trněný, Andrew Davies, Simon Rule, Kim M. Linton, Nina Wagner-Johnston, Randy D. Gascoyne, Graham W. Slack, Pierre Brousset, David A. Eberhard, Francisco J. Hernandez-Ilizaliturri, Gilles Salles, Thomas E. Witzig, Pier Luigi Zinzani, George W. Wright, Louis M. Staudt, Yandan Yang, P. Mickey Williams, Chih-Jian Lih, Jacqueline Russo, Anjan Thakurta, Patrick Hagner, Pierre Fustier, Dale Song, Ian D. Lewis
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (15): 4127–4137.
https://doi.org/10.1158/1078-0432.CCR-16-2818
Published: 01 August 2017
View article titled, A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Open the PDF for A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma

Madeleine Duvic, Youn H. Kim, Pier Luigi Zinzani, Steven M. Horwitz
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (14): 3552–3556.
https://doi.org/10.1158/1078-0432.CCR-16-2064
Published: 13 July 2017
View article titled, Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma
Open the PDF for Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma in another window
Journal Articles

Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Bertrand Coiffier, Weimin Li, Erin D. Henitz, Jayaprakash D. Karkera, Reyna Favis, Dana Gaffney, Alice Shapiro, Panteli Theocharous, Yusri A. Elsayed, Helgi van de Velde, Michael E. Schaffer, Evgenii A. Osmanov, Xiaonan Hong, Adriana Scheliga, Jiri Mayer, Fritz Offner, Simon Rule, Adriana Teixeira, Joanna Romejko-Jarosinska, Sven de Vos, Michael Crump, Ofer Shpilberg, Pier Luigi Zinzani, Andrew Cakana, Dixie-Lee Esseltine, George Mulligan, Deborah Ricci
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (9): 2551–2561.
https://doi.org/10.1158/1078-0432.CCR-12-3069
Published: 30 April 2013
View article titled, Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab
Open the PDF for Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab in another window
Includes: Supplementary data
Journal Articles

Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients

Pier Luigi Zinzani, Giuseppe Rossi, Silvia Franceschetti, Barbara Botto, Alice Di Rocco, Maria Giuseppina Cabras, Maria Concetta Petti, Vittorio Stefoni, Alessandro Broccoli, Stefano Fanti, Cinzia Pellegrini, Gian Carlo Montini, Letizia Gandolfi, Enrico Derenzini, Lisa Argnani, Mariapaola Fina, Alessandra Tucci, Chiara Bottelli, Stefano Pileri, Michele Baccarani
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (15): 3998–4004.
https://doi.org/10.1158/1078-0432.CCR-10-0162
Published: 28 July 2010
View article titled, Phase II Trial of Short-Course R-Chop Followed by <sup>90</sup>Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients
Open the PDF for Phase II Trial of Short-Course R-Chop Followed by <sup>90</sup>Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients in another window
Journal Articles

Pralatrexate Is Synergistic with the Proteasome Inhibitor Bortezomib in In vitro and In vivo Models of T-Cell Lymphoid Malignancies

Enrica Marchi, Luca Paoluzzi, Luigi Scotto, Venkatraman E. Seshan, Jasmine M. Zain, Pier Luigi Zinzani, Owen A. O'Connor
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14): 3648–3658.
https://doi.org/10.1158/1078-0432.CCR-10-0671
Published: 14 July 2010
View article titled, Pralatrexate Is Synergistic with the Proteasome Inhibitor Bortezomib in <em>In vitro</em> and <em>In vivo</em> Models of T-Cell Lymphoid Malignancies
Open the PDF for Pralatrexate Is Synergistic with the Proteasome Inhibitor Bortezomib in <em>In vitro</em> and <em>In vivo</em> Models of T-Cell Lymphoid Malignancies in another window
Includes: Supplementary data